South Korea · Delayed Price · Currency is KRW THE BioMed Statistics
Total Valuation
THE BioMed has a market cap or net worth of KRW 33.25 billion. The enterprise value is 40.37 billion.
| Market Cap | 33.25B |
| Enterprise Value | 40.37B |
Important Dates
The next estimated earnings date is Friday, November 14, 2025.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
THE BioMed has 8.38 million shares outstanding. The number of shares has increased by 33.83% in one year.
| Current Share Class | 8.38M |
| Shares Outstanding | 8.38M |
| Shares Change (YoY) | +33.83% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 7.02% |
| Owned by Institutions (%) | 38.61% |
| Float | 6.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 19.41 |
| PB Ratio | 1.76 |
| P/TBV Ratio | 1.77 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.64 |
| EV / Sales | 23.57 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.58 |
Financial Position
The company has a current ratio of 0.74, with a Debt / Equity ratio of 0.39.
| Current Ratio | 0.74 |
| Quick Ratio | 0.10 |
| Debt / Equity | 0.39 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.47 |
| Interest Coverage | -14.60 |
Financial Efficiency
Return on equity (ROE) is -102.27% and return on invested capital (ROIC) is -28.02%.
| Return on Equity (ROE) | -102.27% |
| Return on Assets (ROA) | -23.73% |
| Return on Invested Capital (ROIC) | -28.02% |
| Return on Capital Employed (ROCE) | -66.43% |
| Revenue Per Employee | 35.69M |
| Profits Per Employee | -514.33M |
| Employee Count | 48 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 0.56 |
Taxes
| Income Tax | -1.23B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -76.44% in the last 52 weeks. The beta is 0.22, so THE BioMed's price volatility has been lower than the market average.
| Beta (5Y) | 0.22 |
| 52-Week Price Change | -76.44% |
| 50-Day Moving Average | 4,893.80 |
| 200-Day Moving Average | 8,008.88 |
| Relative Strength Index (RSI) | 26.74 |
| Average Volume (20 Days) | 17,035 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, THE BioMed had revenue of KRW 1.71 billion and -24.69 billion in losses. Loss per share was -5,190.30.
| Revenue | 1.71B |
| Gross Profit | -2.77B |
| Operating Income | -14.20B |
| Pretax Income | -23.15B |
| Net Income | -24.69B |
| EBITDA | -12.71B |
| EBIT | -14.20B |
| Loss Per Share | -5,190.30 |
Balance Sheet
The company has 272.69 million in cash and 7.39 billion in debt, giving a net cash position of -7.12 billion or -849.96 per share.
| Cash & Cash Equivalents | 272.69M |
| Total Debt | 7.39B |
| Net Cash | -7.12B |
| Net Cash Per Share | -849.96 |
| Equity (Book Value) | 18.92B |
| Book Value Per Share | 3,678.91 |
| Working Capital | -2.86B |
Cash Flow
In the last 12 months, operating cash flow was -6.65 billion and capital expenditures -9.02 billion, giving a free cash flow of -15.67 billion.
| Operating Cash Flow | -6.65B |
| Capital Expenditures | -9.02B |
| Free Cash Flow | -15.67B |
| FCF Per Share | -1,870.53 |
Margins
| Gross Margin | -161.88% |
| Operating Margin | -829.22% |
| Pretax Margin | -1,351.65% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
THE BioMed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -33.83% |
| Shareholder Yield | n/a |
| Earnings Yield | -74.24% |
| FCF Yield | -47.12% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 14, 2025. It was a reverse split with a ratio of 0.1.
| Last Split Date | Apr 14, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
THE BioMed has an Altman Z-Score of -6.27 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.27 |
| Piotroski F-Score | 1 |